1. Academic Validation
  2. 3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: Potent and permeable BACE-1 inhibitors

3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: Potent and permeable BACE-1 inhibitors

  • Bioorg Med Chem Lett. 2020 Apr 15;30(8):126999. doi: 10.1016/j.bmcl.2020.126999.
Aldo Peschiulli 1 Daniel Oehlrich 2 Frederik Rombouts 2 Ann Vos 2 Harrie Jm Gijsen 2
Affiliations

Affiliations

  • 1 Discovery Sciences Medicinal Chemistry, Janssen Research & Development, Janssen Pharmaceutica N.V., Turnhoutseweg 30, Beerse B-2340, Belgium. Electronic address: apeschi@its.jnj.com.
  • 2 Discovery Sciences Medicinal Chemistry, Janssen Research & Development, Janssen Pharmaceutica N.V., Turnhoutseweg 30, Beerse B-2340, Belgium.
Abstract

Since its discovery in 1999, BACE-1, a membrane anchored aspartyl protease expressed primarily in the CNS, has been the target of numerous medicinal chemistry research programs. These efforts have produced highly potent inhibitors with nanomolar affinity and ever-increasing structural complexity. However, only a handful of these molecules have been able to combine in vitro potency with CNS permeability and progressed to the clinic. Herein, we describe a set of novel piperidine-based inhibitors. This investigation culminated with the identification of 43, a highly potent (IC50: 1.5 nM), permeable BACE-1 inhibitor with a low susceptibility to Pgp-mediatedefflux.

Keywords

Alzheimer’s disease; Amidine; BACE inhibitor; pKa; β-Secretase.

Figures
Products